Immunocore

Immunocore:
Developer of the world’s first approved TCR-therapeutic KIMMTRAK and pioneering a new class of therapeutics to deliver transformative medicines to patients in cancer, infection, and autoimmune. KIMMTRAK generated net revenues of $34M in 2Q22 for patients with metastatic uveal melanoma. Durable clinical activity was presented (ESMO 2022) for PRAME in multiple solid tumors and have initiated four expansion arms.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Marketed, Phase III, Phase l or ll
Disease Space
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Infectious Disease, Oncology, Rare Disease
Finance
Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Antibodies, Cell Therapy, Platform Technology
Website:
Profiles:
Address:
Abingdon, Oxfordshire
United Kingdom
United Kingdom
More info:
My account:
Company Participants at Solebury 1x1 Management Access Event 2023
- Bahija Jallal, CEO
- Brian Di Donato, Chief Financial Officer and Head of Strategy
- Clayton Robertson, Head of Investor Relations
- David Berman, Head of R&D
Lead Programs
Kimmtrak
Indication | Phase |
---|---|
metastatic uveal Melanoma | Marketed |
Advanced Melanoma | 2/3 |
Top 10 Holders of Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
RTW Investments LP | 12.27 | 5,559,322 | 283.75 | 13F | 12/31/22 |
Rock Springs Capital Management LP | 7.33 | 3,321,066 | 169.51 | 13F | 12/31/22 |
Baker Bros. Advisors LP | 5.56 | 2,520,731 | 128.66 | 13F | 12/31/22 |
Wellington Management Co. LLP | 4.75 | 2,152,966 | 109.89 | 13F | 12/31/22 |
Fidelity Management & Research Co. LLC | 3.97 | 1,797,746 | 91.76 | 13F | 12/31/22 |
T. Rowe Price Associates, Inc. (Investment Management) | 2.94 | 1,333,916 | 68.08 | 13F | 12/31/22 |
Avidity Partners Management LP | 2.55 | 1,154,000 | 58.90 | 13F | 12/31/22 |
General Atlantic LLC | 2.10 | 950,000 | 48.49 | 13F | 12/31/22 |
Paradigm BioCapital Advisors LP | 1.89 | 857,925 | 43.79 | 13F | 12/31/22 |
Pictet Asset Management SA | 1.36 | 618,315 | 31.56 | 13F | 12/31/22 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.